|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's range||46.81 - 50.11|
|52-week range||12.52 - 105.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||43.78|
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
A week ago, BioNTech SE (NASDAQ:BNTX) came out with a strong set of first-quarter numbers that could potentially lead...
H.C. Wainwright analyst Robert Burns reiterated a Hold rating on BioNTech SE (NASDAQ:BNTX) on Wednesday, setting a price target of $48, which is approximately 3.96% below the present share price of $49.98.
Thank you for joining us today for BioNTech's first-quarter 2020 update call. Before we start, we encourage you to view the slides for this webcast as well as the financial results press release issued this morning, both of which are accessible on our website, in the Investors section. As shown on Slide 2, during today's presentation, we will be making several forward-looking statements.
The big pharma giant will outsource the production of medicines it sells now for a chance to halt the virus responsible for COVID-19 in its tracks.
BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) have dosed the first two U.S. volunteers with a vaccine candidate that could protect people from the coronavirus responsible for COVID-19. The partners began the global clinical trial of the vaccine in April, when they dosed a group of patients in Germany. Traditional drug development is a long process featuring clearly defined steps -- and BioNTech and Pfizer aren't exactly following them.
The U.S. drugmaker and German partner said if the vaccine proves to be safe and effective in trials, it could potentially be ready for wide U.S. distribution by the end of the year, shaving several years off the typical vaccine development timeline. The vaccine, which uses messenger RNA (mRNA) technology, has the potential to be among the first vaccines against the virus that has infected more than 1 million people in the United States and killed some 68,000. There are currently no approved treatments or vaccines for the new coronavirus, though some drugs are being used on patients under an emergency use authorization.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
It was just last week that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) got permission to start a phase 1/2 clinical trial of BNT162, their SARS-CoV-2 vaccine candidate, in Germany. The safety portion of the clinical trial involves testing a range of doses from 1 microgram to 100 micrograms, and will eventually enroll 200 participants. BioNTech has developed four different variations of its mRNA vaccine.
German biotech company BioNTech, which has approval for human trials of potential coronavirus vaccines, has lately received several approaches about a possible takeover but has rejected them, a newspaper reported on Saturday. BioNTech chief Ugur Sahin said the company had been approached by several players in the industry, Welt am Sonntag newspaper quoted him as saying, without identifying any of the potential interested parties. A BioNTech spokeswoman confirmed the content of the interview.
German biotech company BioNTech <22UAy.F>, which has approval for human trials of potential coronavirus vaccines, has lately been contacted by industry players but is not interested in a takeover, a newspaper reported on Saturday. BioNTech chief Ugur Sahin said the company had been approached by several players in the industry in recent weeks, Welt am Sonntag newspaper quoted him as saying, without saying what the subject of the approaches were. A BioNTech spokeswoman confirmed the content of the interview.
Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.
U.S. drugmaker Pfizer Inc <PFE.N> said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus. It also finalized a plan to develop a coronavirus vaccine in partnership with German drugmaker BioNTech SE <22UAy.F> and said the companies hope to produce millions of vaccines by the end of 2020. Data from preclinical studies of a compound that was originally developed to treat SARS - a different coronavirus that caused a major epidemic in 2003 - shows its potential to treat patients with the new coronavirus, Pfizer research chief Mikael Dolsten told Reuters in an interview.
BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.
The joint effort, confirmed Tuesday via a signed letter of intent, will see both partners work together on a messenger RNA-based vaccine that will seek to prevent people from contracting the new coronavirus. It's worth a reminder that any vaccine is going to take, at minimum, between a year and 18 months to develop and certify for general human use, so don't think that this is going to result in any kind of short-term solution. Instead, they rely on RNA to kickstart the production of proteins similar enough to the virus that they trigger the body's development of antibodies effective against the actual target.
The companies said they will finalise financial terms, and details regarding development, manufacturing and potential commercialization of the vaccine over the next few weeks. Reuters reported on Sunday that the German government was trying to stop the U.S. administration from persuading CureVac, another German drugmaker working on an experimental vaccine for the coronavirus, to move its research to the United States. Pfizer and BioNTech will use research and development sites from both companies, including in the United States and Germany, the companies said.
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
Pfizer Chief Scientific Officer Mikael Dolsten was one of the pharmaceutical executives who attended a meeting with U.S. President Donald Trump to discuss possible vaccines and treatments for the fast-spreading virus on Monday. Dolsten said that Pfizer, which already collaborates with BioNTech on the development of mRNA-based vaccines for influenza, is also interested in the company's efforts in coronavirus.